Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now


You can switch off notifications anytime using browser settings.
12,106.90-62.95
Stock Analysis, IPO, Mutual Funds, Bonds & More

Strides Pharma Science Ltd.

AllNewsAnnouncementRecos

BSE LIVE

Change:

Volume:

Open:

Prv. Close:

Today:

Strides Pharma Science Ltd.

52-Wk:

Strides Pharma Science Ltd.

Bid:

()

Offer:

()

NSE LIVE

Change:

Volume:

Open:

Prv. Close:

Today:

Strides Pharma Science Ltd.

52-Wk:

Strides Pharma Science Ltd.

Bid:

()

Offer:

()

Strides Pharma Science Shareholding for the Period Ended December 31, 2019

| Announcement

Strides Pharma Science Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click here

Strides Pharma Science Statement Of Investor Complaints For The Quarter Ended December 2019

| Announcement

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
026260
Name of the Signatory :- Manjula Ramamurthy
Designation :- Company Secretary and Compliance Officer

Strides Pharma Science Announcement under Regulation 30 (LODR)-Newspaper Publication

| Announcement

Newspaper Advertisement of National Company Law Tribunal convened meeting of Equity Shareholders of the Company

Strides Pharma Science Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

Strides announces successful closure of the USFDA inspection at its manufacturing site in Florida, United States

Strides Pharma Science National Company Law Tribunal Convened Meeting Of Equity Shareholders Of The Company To Be Held On February 20, 2020

| Announcement

National Company Law Tribunal convened meeting of Equity Shareholders of the Company to be held on February 20, 2020

Strides Pharma Science Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

Strides receives USFDA approval for Loratadine OTC Softgel Capsules

Strides Pharma Science Disclosure Under Regulation 30 (5) Of The SEBI Listing Regulations

| Announcement

We wish to inform you that Dr. R Ananthanarayanan, Chief Executive Officer and Managing Director of the Company, is also appointed as Key Managerial Personnel of the Company effective January 9, 2020. Accordingly, in terms of SEBI Listing Regulations, he is also authorized to determine materiality of an event or information and to make disclosures to Stock Exchanges as required under the said Regulation. Particulars of Dr. R Ananthanarayanan is as under: Name : Dr. R Ananthanarayanan Designation : Chief Executive Officer& Managing Director Date of Appointment : January 9, 2020 Email id : investors@strides.com Phone : +91 80 6784 0335 Request you to kindly take the above on record.

Strides Pharma Science Announcement under Regulation 30 (LODR)-Change in Directorate

| Announcement

This is to inform you that the Board of Directors of the Company in their meeting held today have approved the following: 1) Appointment of Dr. R Ananthanarayanan (DIN: 02231540) as Chief Executive Officer & Managing Director of the Company effective January 9, 2020, for a period of 5 years, subject to approval of the Members of the Company. Further, he is also appointed as Key Managerial Personnel of the Company effective January 9, 2020. Disclosure under Regulation 30 of the SEBI Listing Regulations for the said appointment is enclosed as Annexure. 2) Re-designation of Mr. Arun Kumar (DIN: 00084845) as Executive Director effective January 9, 2020. Request you to kindly take the above on record.

Strides Pharma Science Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

Please find attached Press Release issued by the Company titled: Dr. R Ananthanarayanan appointed as the new CEO & Managing Director of Strides

Strides Pharma Science Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

| Announcement

Intimation regarding request received for issue of duplicate share certificate under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 V K CHACKO/ KUTTIYAMMA CHACKO

Strides Pharma Science Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

| Announcement

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 03, 2019 for Pronomz Ventures LLP

Strides Pharma Science Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

| Announcement

The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 03, 2019 for Pronomz Ventures LLP

Strides Pharma Science Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

| Announcement

Deepak Bahulal Shah

Strides Pharma Science Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

| Announcement

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 24, 2019 for Pronomz Ventures LLP

Strides Pharma Science Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

| Announcement

E V Manjula

Strides Pharma Science Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

| Announcement

Intimation regarding request received for issue of duplicate share certificate under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 JHONSON V SAMUEL

Strides Pharma Science Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

| Announcement

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 16, 2019 for Devendra Estates LLP

Strides Pharma Science Announcement under Regulation 30 (LODR)-Change in Directorate

| Announcement

This is to inform you that the Board of Directors of the Company by way of circular resolution have appointed Dr. Kausalya Santhanam (DIN: 06999168) as Independent Director of the Company. Dr. Kausalya appointment is for a period of 5 years w.e.f December 11, 2019, subject to approval of the Members of the Company. Enclosed is the disclosure under Regulation 30 of the SEBI LODR for the said appointment.

Strides Pharma Science Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

| Announcement

Pursuant to the above-mentioned Regulations, we wish to inform you that Strides is hosting an Investor/Analyst Day on Thursday, December 5, 2019 to showcase its Biotech division Stelis Biopharma. The meet will be held at the Companys Greenfield Biotech facility in Bangalore and will be attended by a few Analysts and Investors. We would be uploading the presentations proposed to be made to the Investors/ Analysts on the occasion on Companys website at www.strides.com. You are requested to take the above information on record.

Strides Pharma Science Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

Strides receives USFDA tentative approval for Diclofenac Potassium Softgel Capsules

Strides Pharma Science Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

Strides receives USFDA tentative approval for Diclofenac Potassium Softgel Capsules

Strides Pharma Science Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

| Announcement

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 28, 2019 for Shasun Leasing And Finance (P) Ltd and Devendra Estates Pvt Ltd

Strides Pharma Science Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

| Announcement

Intimation regarding request received for issue of duplicate share certificate under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 B SREENIVASA REDDY

Strides Pharma Science Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)

| Announcement

Strides Pharma Science Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here

Strides Pharma Science Outcome Of Postal Ballot

| Announcement

Outcome of Postal Ballot

Sell Strides Pharma Science Ltd. at a price target of Rs 386.0 and a stoploss at Rs 405 from entry point.

Lupin is a 'Buy' call with a target price of Rs 805 and a stop loss of Rs 764.

Strides Pharma Science Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

| Announcement

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 07, 2019 for Nitin Kumar V

Strides Pharma Science Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

Strides announces relaunch of Ranitidine tablets (Rx) for the US Market

Strides Pharma Science Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

USFDA announces Laboratory testing and analysis of Ranitidine and issues statement with acceptable NDMA limits Strides Ranitidine Tablets 300 mg lots tested by USFDA are within the acceptable NDMA limits

Strides Pharma Science Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

| Announcement

Pursuant to the recommendation of Nomination and Remuneration Committee, the Board of Directors of the Company in their meeting held today i.e., October 25, 2019 has granted 25,000 stock options to an eligible employee of the Company under the Strides ESOP 2016 Plan at Rs. 257.65 per option (exercise price). The shares covered by such options are 25,000 equity shares. The vesting period of these options is in a phased manner over a period of 3 years. The options are exercisable within a period of 12 months (exercisable in not more than two tranches) from the date of vesting.

Strides Pharma Science Outcome of Board Meeting

| Announcement

The Board of Directors of the Company in their meeting held today i.e., October 25, 2019 have allotted 3,350 equity shares of face value of Rs. 10/- each to the eligible employees who have exercised their stock options under Strides ESOP 2016 Plan. These shares shall rank in pari passu with the existing equity shares of the Company in all respects. Consequent to above, the paid up share capital of the Company has increased to Rs. 89,55,28,260/- divided into 8,95,52,826 equity shares of Rs. 10/- each.

Strides Pharma Science Outcome Of Board Meeting - Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Half Year Ended S...

| Announcement

We are pleased to enclose the Unaudited Financial Results (Standalone and Consolidated) of the Company along with Limited Review Report of the Statutory Auditors for the quarter and half year ended September 30, 2019, as approved by the Board of Directors of the Company at their meeting held today, along with a press release issued in this regard. The board meeting commenced at 10:30 hrs and concluded at 11:30 hrs. This is for your information and record.

Strides Pharma Science Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

TGA, Australia announces Ranitidine test results

The company said the company's formulations unit in Alathur was inspected by the US Food and Drug Administration (USFDA) in August without any adverse observations.

Strides Pharma Science EIR From USFDA On Continued GMP Status For Formulation Facility At Alathur

| Announcement

EIR from USFDA on continued GMP status for formulation facility at Alathur

Strides Pharma Science Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

| Announcement

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for SBI Funds Management Pvt Ltd

Strides Pharma Science Announcement under Regulation 30 (LODR)-Newspaper Publication

| Announcement

This has reference to our letter dated October 19, 2019 relating to intimation of Board Meeting scheduled to be held on Friday, October 25, 2019 to consider and approve the Unaudited Financial Results (Standalone and Consolidated basis) for the quarter and half year ended September 30, 2019. In compliance with Regulation 30 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, please find enclosed copies of newspaper advertisements published in Business Standard (English Edition) and Lokmat (Marathi Edition), both dated October 19, 2019. This is for your information and records.

Strides Pharma Science Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

| Announcement

Notice of Postal Ballot & E-Voting

Strides Pharma Science Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

Strides receives USFDA approval for Solifenacin Succinate Tablets

Other useful Links


Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service